NADAC acquisition cost data for ATAZANAVIR SULFATE 300 MG CAP. This is a generic medication, typically more affordable than brand-name equivalents.
| Generic Name | atazanavir sulfate |
| Manufacturer | SK BIOTEK IRELAND LIMITED |
| Dosage Form | POWDER |
| Product Type | BULK INGREDIENT |
| NDC | NADAC/Unit | Effective Date | Type |
|---|---|---|---|
| 00093552856 | $3.50 | 2022-10-19 | Rx |
| 16714086201 | $3.50 | 2022-10-19 | Rx |
| 31722065530 | $3.50 | 2022-10-19 | Rx |
| 42385092230 | $3.50 | 2022-10-19 | Rx |
| 65862071330 | $3.50 | 2022-10-19 | Rx |
| 69097044602 | $3.50 | 2022-10-19 | Rx |
| 69238113803 | $3.50 | 2022-10-19 | Rx |
| 00093552856 | $3.50 | 2022-10-19 | Rx |
| 16714086201 | $3.50 | 2022-10-19 | Rx |
| 31722065530 | $3.50 | 2022-10-19 | Rx |
Generic: Atazanavir Sulfate | Manufacturer: Overall
| Year | Total Spending | Claims | Beneficiaries | Cost/Unit |
|---|---|---|---|---|
| 2019 | $19.8M | 37,194 | 5,381 | $14.58 |
| 2020 | $15.4M | 29,353 | 3,644 | $13.35 |
| 2021 | $10.9M | 21,584 | 2,882 | $11.97 |
| 2022 | $8.5M | 16,664 | 2,298 | $11.64 |
| 2023 | $7.5M | 13,153 | 1,861 | $12.41 |
| State | Total Cost | Claims | Beneficiaries |
|---|---|---|---|
| New York | $1.1M | 1,641 | 236 |
| California | $1.1M | 1,992 | 331 |
| Florida | $707.0K | 1,252 | 178 |
| Texas | $434.0K | 718 | 121 |
| New Jersey | $370.0K | 545 | 82 |
| Georgia | $327.2K | 643 | 80 |
| Illinois | $265.0K | 506 | 64 |
| Louisiana | $218.3K | 432 | 56 |
| Pennsylvania | $215.5K | 369 | 51 |
| Virginia | $214.6K | 368 | 57 |
| Massachusetts | $204.2K | 342 | 51 |
| Tennessee | $191.6K | 278 | 40 |
| Maryland | $186.9K | 318 | 49 |
| Ohio | $170.1K | 309 | 46 |
| North Carolina | $144.0K | 327 | 46 |
| Puerto Rico | $142.8K | 322 | 39 |
| Washington | $133.1K | 303 | 42 |
| Connecticut | $128.3K | 181 | 25 |
| Kentucky | $88.3K | 198 | 22 |
| Mississippi | $86.6K | 182 | 21 |
| Minnesota | $71.1K | 108 | 17 |
| Hawaii | $70.8K | 98 | 18 |
| Colorado | $68.0K | 138 | 24 |
| Oregon | $66.3K | 110 | 22 |
| Michigan | $64.5K | 118 | 23 |
| Missouri | $64.0K | 134 | 18 |
| Arizona | $59.4K | 115 | 19 |
| Kansas | $58.6K | 91 | 12 |
| Iowa | $56.7K | 68 | N/A |
| Oklahoma | $54.1K | 48 | N/A |
| South Carolina | $53.4K | 168 | 14 |
| Alabama | $47.2K | 113 | 17 |
| District of Columbia | $39.6K | 62 | 12 |
| New Mexico | $37.1K | 43 | N/A |
| Indiana | $35.6K | 64 | 13 |
| Arkansas | $35.5K | 98 | N/A |
| Vermont | $28.6K | 41 | N/A |
| Wisconsin | $24.1K | 31 | N/A |
| New Hampshire | $18.6K | 26 | N/A |
| Nevada | $18.0K | 39 | N/A |
| Rhode Island | $17.1K | 20 | N/A |
| Utah | $13.3K | 25 | N/A |
| Maine | $12.1K | 19 | N/A |
| North Dakota | $11.4K | 25 | N/A |
| Virgin Islands | $7.4K | 13 | N/A |
| West Virginia | $6.4K | 26 | N/A |
| Delaware | $6.1K | 19 | N/A |
| Wyoming | $3.0K | 11 | N/A |
| Idaho | $2.7K | 12 | N/A |
| Alaska | $2.5K | 26 | N/A |
The DrugPricePeek editorial team aggregates and verifies drugs data from CMS NADAC & Medicare Part D. Every statistic on this site is cross-referenced against the official source before publication, with quarterly re-verification cycles.
Read our full methodology or contact us with corrections.